NCT00003641 2026-02-25
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
Clinical Trials
4 trialsNCT02694965 2024-02-14
Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma
Duke University
Completed
NCT04625491 2021-02-10
Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor.
Hospital Universitario Virgen de la Arrixaca
Unknown
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn